<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00572689</url>
  </required_header>
  <id_info>
    <org_study_id>Exenatide.GDM</org_study_id>
    <secondary_id>202-801-2636</secondary_id>
    <nct_id>NCT00572689</nct_id>
  </id_info>
  <brief_title>Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes</brief_title>
  <official_title>Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Washington Hospital Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to study how exenatide, an FDA-approved drug that lowers blood sugar
      in non-pregnant patients with type II diabetes, works in pregnant women. To do this, we will
      study the drug's pharmacokinetics (what the body does to the drug; specifically, how quickly
      your body breaks down and excretes exenatide) and pharmacodynamics (what the drug does to the
      body; specifically, how effectively exenatide helps your pancreas secrete insulin and how
      well it controls blood sugar after a meal). There are only two main drug therapies (insulin
      injections and glyburide pills) currently used for gestational diabetes and not all women
      achieve good enough blood sugar control without side effects. Therefore, we hope to find out
      if exenatide might also be helpful in gestational diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glycemic control through insulin, glucose, c-peptide and glucagon assays</measure>
    <time_frame>duing testing days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TCF7L2 polymorphism</measure>
    <time_frame>During subject testing days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exenatide Pharmacodynamics and Pharmacokinetics</measure>
    <time_frame>During testing days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Gestational Diabetes</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject receives injection of 10 micrograms of Exenatide sub-cutaneously the given mixed meal test and blood samples will be drawn for laboratory testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients given mixed meal test and blood samples drawn for laboratory testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>10 microgram injected sub-cutaneously once</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Buccal/blood Sample Collection</intervention_name>
    <description>Buccal/blood Sample collection for TCF7L2 polymorphism genetic testing</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women (singleton)

          -  Gestational diabetes not requiring medical therapy

          -  Between 18 and 50 years of age

          -  Able to give written informed consent

        Exclusion Criteria:

          -  Women in the first trimester of pregnancy

          -  Hematocrit less than 30%

          -  Current or past treatment with any hypoglycemic agent

          -  Women with gastrointestinal disease or symptoms consistent with nausea, vomiting,
             abdominal pain or reflux requiring medical treatment.

          -  Women with high triglyceride levels, history of gallbladder or pancreatic disease.

          -  Clinical diagnosis or history of any renal insufficiency (or decreased creatinine
             clearance)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason G Umans, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University Medical Center, Medstar Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maisa N Feghali, MD</last_name>
    <role>Study Director</role>
    <affiliation>Washington Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2007</study_first_submitted>
  <study_first_submitted_qc>December 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2007</study_first_posted>
  <last_update_submitted>August 20, 2015</last_update_submitted>
  <last_update_submitted_qc>August 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgetown University</investigator_affiliation>
    <investigator_full_name>Jason Umans</investigator_full_name>
    <investigator_title>Prinipal Investigator</investigator_title>
  </responsible_party>
  <keyword>Exenatide</keyword>
  <keyword>TCF7L2 polymorphism</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

